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Summary:
A fludarabine-based protocol (fludarabine (25mg/m2/
day 6 days), cyclophosphamide (10mg/kg/day 2 days)
and ATG (ATGAM 10mg/kg/day 4 days)) was used in
four multiply transfused Fanconi’s anemia (FA) patients
aged 5–15 years to reduce rejection during allogeneic bone
marrow transplantation (BMT). Graft-versus-host disease
(GVHD) prophylaxis consisted of cyclosporine and mini
methotrexate. The graft source was G-CSF-stimulated
bone marrow or peripheral blood stem cells (PBSC) in two
patients each. All patients engrafted with median time
to ANC4500/mm3 being 14 days (range: 12–17) and
unsupported platelet count 420 ,000/mm3 being 13 days
(range: 11–18). One patient had secondary graft rejection
on day 56 and expired on day 69 due to fungal pneumonia.
One patient who developed acute myeloid leukemia on day
56 underwent successful induction with cytosine and
daunorubicin followed by peripheral blood stem cell
(PBSC) rescue on day 70 and is presently in remission
with complete donor chimerism and grade I GVHD. At a
median follow-up of 13 months (range: 4–21), three
patients (75%) are well with complete donor chimerism.
Addition of fludarabine to the conditioning regimen for
BMT in FA can provide additional immunosuppression for
engraftment without increasing toxicity.
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Allogeneic bone marrow transplantation (BMT) has
produced excellent survival rates in patients with Fanconi’s
anemia (FA) using low-dose cyclophosphamide with or
without radiation therapy.1 Graft rejection rates of 30–60%
occur in multiply transfused patients with aplastic anemia
requiring intensification of immunosuppression.2 Few
case reports exist on the use of fludarabine-based proto-
cols as conditioning regimens for patients with FA with
encouraging results3–8 and we describe our experience in
multiply transfused FA patients.
Patients and methods
Between 1999 and 2003, four male patients with FA
underwent six antigen-matched sibling or family donor
BMT at our center. The diagnosis of FA was confirmed by
stress cytogenetics using mitomycin C and all had a bone
marrow aspirate suggestive of aplastic anemia done 3–6
months prior to BMT. Standard karyotyping was not
performed. Conditioning regimen consisted of fludarabine
25mg/m2/day (day 11 to 6); cyclophosphamide 10mg/
kg/day for 2 days (days 7 and 6), antithymocyte
globulin (ATGAM, Pharmacia Upjohn, USA) 10mg/kg/
day for 4 days (days 5 to 2). Graft source was either
G-CSF-stimulated bone marrow or G-CSF-stimulated
peripheral blood stem cells (PBSC) in two patients each.
Supportive care
Patients were nursed in HEPA-filtered rooms with ade-
quate sterile precautions and barrier nursing. G-CSF (5 mg/
kg/day) was started on day þ 7 following the infusion of
bone marrow or PBSC. Broad-spectrum antibiotics and
antifungals were administered as per existing protocols for
febrile neutropenia. Acyclovir and Septran were adminis-
tered as CMV and Pneumocystis carinii prophylaxis,
respectively. Ganciclovir was administered started as pre-
emptive prophylaxis if the CMV polymerase chain reaction
(PCR) became positive. Graft versus host disease (GVHD)
prophylaxis consisted of cyclosporine (3mg/kg/day i.v.
starting day 1) and mini methotrexate (5mg/m2 days 1, 3
and 6). Acute GVHD was treated with either dexametha-
sone or methylprednisolone.
Results
There were a total of four patients (all male) with a median
age of 10 years (range: 5–15). The median duration from
diagnosis to BMT was 34.5 months (range: 20–60) and the
median number of packed red cells transfused prior to
BMT was 28 (range: 22–45).
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Graft
The mean cell dose infused was 10.3 108 nucleated cells/
kg (range: 4.6–16) for G-CSF-stimulated bone marrow,
while it was 9.1 108 nucleated cells/kg (range: 6.1–12) for
PBSC (Table 1).
Toxicity, engraftment and GVHD
Toxicity was minimal with only grade I mucositis seen in
two patients. All patients engrafted with a time to
ANC4500/mm3 ranging between 12 and 17 days and
ANC41000/mm3 ranging between 13 and 18 days. An
unsupported platelet count 420 000/mm3 was achieved
between 11 and 18 days. During the first 30 days,
1–2 packed cells and 10–12 platelet transfusions were
given. Three patients received G-CSF to hasten engraft-
ment for 2–5 days. None of the patients developed acute
GVHD.
Hospital course following BMT
Patient No 1 developed secondary graft rejection on day 50
after BMT and expired on day 69 due to fungal pneumonia.
Patient No 4 had a complete chimerism on day þ 21, but
was found to have immature cells in the peripheral blood
on day 56 with a mixed chimerism. Bone marrow aspirate
revealed 54% blasts, suggestive of AML – M5 with
cytogenetic analysis showing a complex karyotype {46-47
XY, add(2)(q37), add(3)(q26), dup(3)(q21q26), del(7)(q22),
ins(12)(q13), del(20)(q11), þmar [cp20]}. He had induction
chemotherapy with cytosine (200mg/m2/day continuous
infusion for 7 days) and daunorubicin (45mg/m2/day for 3
days). The day 14 and day 28 marrows did not show any
evidence of residual disease. He had a peripheral blood
stem cell (PBSC) rescue using the original donor on day 70
(cell dose: 12.3 108 MNC/kg) and is presently in
remission with complete donor chimerism 120 days post
BMT (day 50 following DLI) with grade I gastrointestinal
acute GVHD. Patient Nos. 2 and 3 had an uneventful
hospital stay.
Survival and follow-up
At a median follow-up of 13 months (range 4–21), three
patients (75%) are alive and well with complete donor
chimerism.
Discussion
The unique sensitivity of FA cells to DNA crosslinking
agents has led to the use of low-intensity conditioning
regimens (low-dose cyclophosphamide with thoracoab-
dominal radiation (Cy/TBI) or low-dose cyclophosphamide
(Cy) alone) during BMT to reduce toxicity.9 These
regimens, however, have not been immunosuppressive
enough to reduce graft rejection in patients who are heavily
transfused. Fludarabine-based protocols have the twin
advantage of potent immunosuppression, thus reducing
the incidence of graft rejection along with minimal regimen-
related toxicity. No patient had any major toxicity
associated with this conditioning regimen and initial
engraftment was seen in all patients though one patient
had a secondary graft rejection on day þ 50. Acute GVHD
was not seen initially in any of our patients though one
patient developed grade I GVHD following the PBSC
rescue. The incidence of GVHD in our series is quite low
compared to the incidence of 50–60% seen in patients
transplanted using Cy/TBI or Cy alone regimens with the
majority of them also developing chronic GVHD.9
Approximately 16 patients with FA treated with fludar-
abine-based regimens have been described in the literature,
and the incidence of regimen-related toxicity (RRT) has
been minimal with nil to grade I–II GVHD3–8 with all
patients showing engraftment. Only Guardiola et al in their
report of three patients, where fludarabine-based regimens
were used for a second transplant, showed fatal grade IV
GVHD in two of the three patients.10 Fludarabine-based
conditioning regimens have been used effectively with early
stable engraftment and minimal toxicity in patients with
poor risk for conventional myeloabalative therapy. An
ideal conditioning regimen would be one that combines
Table 1 Patient characteristics, engraftment, GVHD and follow-up
Patient 1 Patient 2 Patient 3 Patient 4
Age/sex 15/M 12/M 8/M 5/M
Symptom duration 60 28 20 30
Prior transfusions 45 22 22 24
Prior treatment received Stanazolol/prednisolone Stanazolol/prednisolone ALG/cyclosporine Stanazolol/prednisolone
Source/cell dose GCSF-BM GCSF-PBSC GCSF-BM GCSF-PBSC
( 108 TNC/kg) 4.69 6.1 16 12
ANC4500/mm3 15 12 17 12
ANC41000/mm3 15 13 18 14
Platelet count 420 000/mm3 18 11 15 11
GVHD Nil Nil Nil Nil/grade I after PBSC
rescue
Complications Secondary graft failure day
50
Nil Nil AML day 56 – induction
with cytosine/daunorubicin
Follow-up Expired day 69 Well 21 months Well 16 months Well 4 months
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adequate engraftment with minimal toxicity and fludar-
abine-based protocols seem to come close to this definition.
However, longer follow-up is required to evaluate late
rejection and long-term effects in children.
In conclusion, fludarabine-based conditioning regimens
are associated with early engraftment with minimal toxicity
in patients with FA who are multiply transfused and where
rejection rates are expected to be higher.
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